Mirna Therapeutics, one of the biotechnology firms in the United States introduced a new member in its board of directors. Dr. Clay B. Siegall will be the new outside director of the board. Mirna Therapeutics specializes in the development and commercialization of microRNA therapeutics.
Dr. Clay B. Siegall is not new in this industry. He is actually the founder of a company known as Seattle Genetics. Dr. Clay also serves as the Chief Executive Officer and President of the institution. As the CEO of Seattle Genetics, Dr. Clay is the chairman of the board of directors, and he oversees the daily operations of the company. Under his leadership, the company has grown in the recent past. He has also of expertise in biotechnology, and he holds a Ph.D. in the same industry.
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
The Mirna Therapeutics team is excited to have Dr. Clay Siegall in their board. Dr. Clay will be expected to introduce several changes in Mirna Therapeutics, having worked in the pharmaceutical world for many years. Dr. Clay was able to build one of the most powerful oncology companies in the world. The Mirna team will benefit from this knowledge, especially when developing the microRNA therapeutics.
MicroRNA therapeutics is an exciting area in cancer research. Mirna Therapeutics is among the firms that have the knowledge and tools to produce the right products in this area. Dr. Clay is expected to part of the team that will be involved in miRNA, and he looks forward to advance the programs in the company that will help the increasing cancer patients in the world.
Dr. Siegall started Seattle Genetics in1998. Under his leadership, the company has been able to develop a variety of antibody therapies that easy address different medical need for the individuals suffering from cancer. Seattle Genetics produced its first commercial product several years ago, and it was approved to sell in the market in 2011. The product, known as ADCETRIS has done very well in the market. Dr. Clay has also partnered with other pharmaceutical and biotechnology companies in the oncology industry to come up with better drugs for cancer patients in the past.